By Evans Matthews
For decades, the journey from drug concept to pharmacy shelf has been long, costly, and uncertain. Developing a single new drug often takes more than ten years and costs billions of dollars, with a high risk of failure. Today, artificial intelligence (AI) is rewriting that story—cutting timelines, improving success rates, and giving both local and global pharmaceutical industries a technological edge.
AI’s strength lies in its ability to process vast datasets, predict molecular behavior, and identify promising compounds far faster than traditional methods. By analyzing genetic data, chemical structures, and historical trial results, AI can uncover insights that might take human researchers years to find.
In Nigeria, researchers are already seeing the potential. “AI is helping us leapfrog infrastructure gaps,” says Dr. Aisha Bello, computational biologist at Lagos Biomedical Research Centre. “Instead of spending years on preliminary screening, we can identify viable drug targets in weeks. This speed is critical for diseases like malaria, sickle cell anemia, and Lassa fever that disproportionately affect Africa.”
Internationally, the story is similar—albeit at a larger scale. During the COVID-19 pandemic, AI platforms from companies like BenevolentAI (UK) and Insilico Medicine (Hong Kong) rapidly analyzed existing drug libraries, pinpointing potential treatments in months rather than years. Some of these candidates quickly advanced to trials, demonstrating AI’s ability to respond to urgent global health crises.
One of AI’s biggest breakthroughs is in target identification—determining the biological molecule a drug should act upon. AI algorithms scan genomic and proteomic data to pinpoint these targets, drastically reducing early-stage research time.
Equally transformative is AI-driven molecule design. Using generative models, scientists can create new chemical structures tailored for potency, safety, and stability—before they are physically made. This not only cuts costs but also boosts the odds of finding successful candidates.
“Before AI, we might screen hundreds of thousands of molecules to find a handful worth testing,” says Dr. Raymond Cole, head of research at BioPharmaX in the United States. “Now, we can focus on a few dozen high-potential compounds from the start.”
In Nigeria and across Africa, AI is also fueling drug repurposing—finding new uses for approved drugs. This is particularly valuable where budgets for entirely new drug development are limited. By cross-referencing molecular profiles with disease mechanisms, AI can propose cost-effective treatments that are faster to roll out.
AI’s influence extends to clinical trials, one of the costliest phases in drug development. In both Lagos and London, AI tools are being used to identify ideal patient groups, predict adverse reactions, and even simulate trial outcomes, reducing time and improving safety.
Challenges remain. Regulatory agencies in Nigeria, such as NAFDAC, are still crafting guidelines for AI-driven research, while globally questions about data quality and transparency persist. The success of AI models depends heavily on the integrity and diversity of the datasets they’re trained on—a particular concern in regions with limited biomedical data infrastructure.
Still, momentum is building. Analysts predict AI will help bring dozens of new drugs to market within the next decade, with timelines cut by up to 70 percent.
As Dr. Bello notes, “AI won’t replace scientists—it will supercharge them. The winners will be those who combine human creativity with machine precision.”
In a world where every month can mean lives saved, AI in drug discovery is more than innovation—it’s a lifeline, both in bustling labs in Boston and in the growing biotech hubs of Lagos and Nairobi.
English